Common Contracts
9 similar Letter Agreement contracts by Apellis Pharmaceuticals, Inc., NuCana PLC, Immunovant, Inc., others
Immunovant, Inc. (a Delaware corporation) 7,370,000 Shares of Common Stock UNDERWRITING AGREEMENTLetter Agreement • September 28th, 2023 • Immunovant, Inc. • Biological products, (no disgnostic substances) • New York
Mirum Pharmaceuticals, Inc. 3,478,261 Shares Common Stock ($0.0001 par value) Underwriting AgreementLetter Agreement • August 10th, 2022 • Mirum Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Mirum Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 3,478,261 shares of common stock, $0.0001 par value (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 521,739 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I hereto other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires.
Apellis Pharmaceuticals, Inc. 7,446,809 Shares Common Stock ($0.0001 par value per share) Underwriting AgreementLetter Agreement • March 25th, 2022 • Apellis Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Apellis Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 7,446,809 shares of common stock, $0.0001 par value per share (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 1,117,021 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the contex
Apellis Pharmaceuticals, Inc. 8,750,000 Shares Common Stock ($0.0001 par value per share) Underwriting AgreementLetter Agreement • November 17th, 2021 • Apellis Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Apellis Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 8,750,000 shares of common stock, $0.0001 par value per share (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 1,312,500 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the contex
Owens & Minor, Inc. 8,475,000 Shares Common Stock ($2 par value per share) Underwriting AgreementLetter Agreement • October 6th, 2020 • Owens & Minor Inc/Va/ • Wholesale-medical, dental & hospital equipment & supplies • New York
NuCana plc 15,555,556 American Depositary Shares Representing an Aggregate of 15,555,556 Ordinary Shares Underwriting AgreementLetter Agreement • September 18th, 2020 • NuCana PLC • Pharmaceutical preparations • New York
The ADSs will be evidenced by American Depositary Receipts (“ADRs”) issued pursuant to that certain Deposit Agreement, dated as of October 2, 2017 (the “Deposit Agreement”), by and among the Company, Citibank, N.A. as depositary (the “Depositary”), and all holders and beneficial owners of ADSs issued thereunder. The Company shall, following subscription by the Underwriters of the Offered Securities pursuant to this Agreement, deposit, on behalf of the Underwriters, the Shares being delivered in the form of the Offered Securities with Citibank, N.A., London Branch as custodian (the “Custodian”) for the Depositary, which shall deliver the Offered Securities to the Representatives for the account of the several Underwriters for subsequent delivery to the other several Underwriters or the investors, as the case may be.
Apellis Pharmaceuticals, Inc. 9,500,000 Shares Common Stock ($0.0001 par value per share) Underwriting AgreementLetter Agreement • January 9th, 2020 • Apellis Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Apellis Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 9,500,000 shares of common stock, $0.0001 par value per share (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 1,425,000 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the contex
Apellis Pharmaceuticals, Inc. 6,000,000 Shares Common Stock ($0.0001 par value per share) Underwriting AgreementLetter Agreement • March 7th, 2019 • Apellis Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Apellis Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 6,000,000 shares of common stock, $0.0001 par value per share (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 900,000 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context
NuCana plc [●] American Depositary Shares Representing An Aggregate of [●] Ordinary Shares Underwriting AgreementLetter Agreement • September 18th, 2017 • NuCana PLC • Pharmaceutical preparations • New York
The ADSs will be evidenced by American Depositary Receipts (“ADRs”) issued pursuant to that certain Deposit Agreement dated [●], 2017 (the “Deposit Agreement”), by and among the Company, Citibank, N.A. as depositary (the “Depositary”), and all holders and beneficial owners of ADSs issued thereunder. The Company shall, following subscription by the Underwriters of the Offered Securities pursuant to this Agreement, deposit, on behalf of the Underwriters, the Shares being delivered in the form of the Offered Securities with Citibank, N.A., London Branch as custodian (the “Custodian”) for the Depositary, which shall deliver the Offered Securities to the Representatives for the account of the several Underwriters for subsequent delivery to the other several Underwriters or the investors, as the case may be.
